Fortis Frontier Plc · LSE:FORF
Fortis Frontier — MyHealthChecked — Investor Presentation (January 2021)
30 slides from Fortis Frontier's investor presentation, January 2021
Slide 1: MyHealthChecked Investor Presentation
www.myhealthcheckedplc.com Investor Presentation | CONFIDENTIAL 1
Slide 2: Document information
Document information IMPORTANT NOTICE This document, which has been prepared by, and is the sole responsibility of, MyHealthChecked plc (the "Company"), has been prepared solely in connection with the proposed placing of new ordinary shares of 0.1 pence each in the capital of the Company (the "Placi
Slide 3: Leadership with proven experience in technical & commercial growth
Leadership with proven experience in technical & commercial growth Presenting today Dr Karen Whiting Amy Howarth Jane Kelly Bhavika Patel Penny McCormick Maddy Kennedy • A team CEO CFO CTO Marketing Manager Operations Manager Product Specialist building in • 15 years in medical • Proven CFO for • 20
Slide 4: Backed by experienced NEDs and Mercia as major shareholder
Backed by experienced NEDs and Mercia as major shareholder Presenting Experts in commercialisation Adam Reynolds Peter Dines Neil Mesher Lyn Rees and investment of IVDs and Chairman Non-Exec Director Non-Exec Director Non-Exec Director consumer technology Chairman, investor and NED COO Mercia Asset
Slide 5: MyHealthChecked Plc
MyHealthChecked Plc Bringing Simple, Reliable, Affordable health tests to market - now New management team who have built a new strategy in 2020. We have invested to grow We are seeking to in 2021 and beyond become the UK’s leading B2C POC testing We have added and will further add new tests t
Slide 6: Today we're here to invest in and grow our at-home testing business
Today we’re here to invest in and grow our at-home testing business From here To unlocking a greater opportunity Fertility Single MULTIPLE PLATFORMS Lateral Flow DNA + more Platform 2 LIMITLESS TESTS Tests 640,000 UK women successful Multi sector approach opening the door to the $16bn* at home conce
Slide 7: We have a simple, affordable value proposition
We have a simple, affordable value proposition: 7
Slide 8: Evolution into the significant opportunity of DNA testing
Evolution into the significant opportunity of DNA testing • DNA testing is being used increasingly as an indicator of your biology by the industry at large • CAGR for at-home testing kit market is 6.8%, from $8.87bn in 2019 to $16bn by 2027* • Direct-to-Consumer Genetic Testing Market to hit $2.5 Bn
Slide 9: Genomics & genetic testing: a new mainstream for the 21st century
Genomics & genetic testing: a new mainstream for the 21st century At-home Genetic testing was in its infancy 10 years ago ‘’We’re no longer forecasting change – we’re watching it Exponential growth over the next 3 years happen’’. 1Thomas Barlow, GIMR, 2018 2023 100,000,000 It’s an early and exciting
Slide 10: Now: Home testing is a growing market with significant white space
Now: Home testing is a growing market with significant white space due to 1. Change in mindset COVID-19 making home testing more desirable and expected 2. Behaviour changing avoidance of physical attendance for many interactions – remote communication the new normal 3. Familiarity “The COVID-19 pand
Slide 11: 2021 and 2022 product discovery targets
2021 and 2022 product discovery targets INTOLERANCE FEMALE NUTRITION SKIN & BEAUTY REPRODUCTIVE HEALTH Lactose (DEFICIENCY RISK) Collagen Coeliac Pre-Pregnancy & Pregnancy Vitamin A Wrinkles (premature aging) Alcohol Folate NUTRITION Vitamin B Acne Homocysteine Caffeine Vitamin B12 Glycation Vitamin
Slide 12: Driving a dynamic roadmap ahead
Driving a dynamic roadmap ahead Delivering multiple product launches in 2021 and beyond to update the stock market with progress and key milestones Feb 21 Investment Up to £3m Oct 20 Nov 20 Dec 20 Jan 21 Feb 21 Mar 21 Apr 21 Jul 21 Oct 21 Mar 22 Jun 22 Jul 22 Detailed TGS Covid test Campaign ISO 151
Slide 13: How our tests are different
How our tests are different At MyHealthChecked our tests: 1. Deliver results fast – days not weeks 2. Are priced attractively - £20 - £30 for core single range (aside from Covid tests) 3. Use scientifically validated, highly significant genetic markers 4. Are based on published evidence in the most
Slide 14: Agile, flexible, and able to react
Agile, flexible, and able to react Our fully flexible testing model allow us to be market reactive, whilst cost effective For Example: COVID-19 Severity A genome wide association study involving 1980 patients with COVID-19 and severe disease (defined as respiratory failure) has been conducted at sev
Slide 15: Ability to create superior products
Ability to create superior products Coeliac Disease Tests with 99% accuracy are HLA-DQ2.5 Most common brought to market by trusted, accredited, approved provider HLA-DQ8 Less common HLA-DQ2.2 Least common x x Intolerance Range Our skilled team identifies the most accurate, proven
Slide 16: Why customers will choose MyHealthChecked
Why customers will choose MyHealthChecked Affordable Driven in-house with premium products and service at affordable prices Validated cherry-picked specialists to Simple well established by target and engage users via: clear, actionable results scientific experts, from each test supported by - Paid
Slide 17: We have created and commenced delivery of these market opportunities
We have created and commenced delivery of these market opportunities Milestones delivered: Growth outcomes: • New management team Full regreening of team under new leadership • DTC revenue generation Launch of business and commercialisation • Cash preservation Refocused the business through adjus
Slide 18: Initial potential for pipeline development: UK
Initial potential for pipeline development: UK Test Prevalence* Units Addressable 0.5% share 1% share 5% share market Lactose 15% 9.9m £297m £1.5m £3m £15m We have the potential Gluten 13% 8.6m £258m £1.3m £2.6m £13m to own an increasing Caffeine 10% 6.6m £198m £1m £2m £10m % of the addressable mark
Slide 19: Our 3-year horizon
Our 3-year horizon 2021 2022 2023 Intolerance, Women’s Health, Fertility + Healthcare, Beauty (eg: premature + Portfolio aging) Web App development B2B Business development: Brands, Expanding capabilities insurance providers DTC, Amazon, Retail Mobile App UK Complimentary product recommendations Eur
Slide 20: Placing, use of proceeds and timetable
Placing, use of proceeds and timetable Increase in headcount to Expenses We are raising up to £3m investment to support commercial activities Compliance 3% • Launch into retail 15.00 Research & • Build awareness Development Sales & 9% Marketing • Develop a pipeline of new products 10.00 32% • Develo
Slide 21: To conclude. Thank you
To conclude MHC has the right cost base, the right team, the right partners and the right strategy to capture a significant growth market from consumers We are generating revenue with more covid opportunities ahead, whilst developing new products to launch in 2021 and beyond We have clear strate
Slide 22: Appendix 1: Competitive Products
Appendix 1: Competitive Products Non DNA Based Single Tested Available App Access Concise UK Price Invasive Test Test in-house on High St to Data Reporting Product £ £££ x N/A ££ x x x N/A ££££ x N/A x x ££££ x N/A x ££££ x ££££
Slide 23: Appendix 2: Population, Prevalence and Perception
Appendix 2: Population, Prevalence and Perception Symptoms Self-diagnose Interested Validation Impulse why do you get you believe what diet is best you’ve told friends the tests are reasons headaches, feel you’re lactose for you to gain and family you inexpensive, right nauseous, have intolerant but
Slide 24: Appendix 3: Customer Journey - How It Works
Appendix 3: Customer Journey - How It Works Simple Process, <2 weeks to Results ✐ PRODUCT REGISTRATION POST TO SAMPLE DATA ANALYSIS & RESULTS PURCHASED & COLLECTION MyHealthChecked PROCESSING INTREPRETATION REPORTED Product purchased Customer registers Freepost – Royal Mail Sample registration, Anal
Slide 25: Appendix 4: Product Use
Appendix 4: Product Use Kit registration is completed via website (App in development) 1. Enter your barcode 2. Submit your details 3. Wait for your user details 25
Slide 26: Appendix 5: Customer Results
Appendix 5: Customer Results Joe Bloggs 26
Slide 27: Appendix 6: Financial History
Appendix 6: Financial History £’000 2018 2019 2020* Sales 4.8 32.0 54.7 £3.0m £60.0k Cost of sales -75.3 -77.1 -246.5 Gross Margin -70.4 -45.1 -191.8 £2.5m £50.0k Operations 487.9 418.0 152.9 £2.0m £40.0k Gross Profit -558.3 -463.1 -344.7 £1.5m £30.0k R&D 564.8 223.0 535.0 £1.0m £20.0k Sales and mar
Slide 28: Appendix 7: Our legacy fertility portfolio
Appendix 7: Our legacy fertility portfolio • Quantitative lateral flow technology for key fertility hormones, under development with PdG test capability and Smartphone reader • Market presence upon which to add highly relevant testing platforms (PCOS, pre-fertility) • Adjusted strategy as Covid impa
Slide 29: Appendix 8: Corporate use of funds
Appendix 8: Corporate use of funds • Re-established Mylo as relevant and correctly positioned • Secured future tech and commenced improvements and development • Adjusted strategy as Covid impacted model • Market-responsive to accelerate revenue in light of pandemic Lease Technology assignment to tra
Slide 30: Appendix 9: Corporate Information
Appendix 9: Corporate Information Shareholder Ordinary Shares Issued Share Capital (%) *The total holding for Mercia Asset Management includes Share Nominees LTD (Mercia EIS Fund)* 62,500,000 12.1 - Share Nominees Limited (Mercia EIS Fund) Mercia Investment Plan LP* 59,336,428 11.5 - Mercia Investme
MyHealthChecked — Investor Presentation (January 2021) on 6ix